AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04485611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic + resistance training and nutritional support
Description: The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
Study NCT05409456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild aerobic exercise
Description: mild aerobic exercise given to group A on treadmill
Study NCT05409456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate aerobic exercise
Description: moderate aerobic exercise given to group B on treadmill
Study NCT05838781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk prediction model
Description: A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
Study NCT05838781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 14-days continuous ECG monitoring
Description: 14-days continuous ECG monitoring with an ECG patch.
Study NCT05903222 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: This study is a non-interventional study of all patients previously enrolled in the PALACS trial
Study NCT05064709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System
Description: The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
Study NCT05064709 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: OPTIMIZER™ Smart Mini System
Description: The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
Study NCT06110689 — intervention group
Intervention type: OTHER
Intervention: VU-AMS device
Description: Patients will wear the VU-AMS monitor prior to MRI.
Study NCT05335187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-macro electrode implantation
Description: One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
Study NCT06384040 — intervention group
Intervention type: PROCEDURE
Intervention: platelet-rich plasma knee injection
Description: platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
Study NCT05377385 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about usability of the Omnipod DASH insulin administration system
Study NCT05130814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light photobiomodulation
Description: 1 minute irradiation of blue light performed with EmoLED device.
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleansing
Description: cleaning of the wound area with saline or ringer's lactate
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing
Description: cleaning of the wound area with saline or ringer's lactate
Study NCT05130814 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid gauze plus polyurethane foam
Description: every 48 hours or as needed
Study NCT05130814 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gauze plus polyurethane foam
Description: every 48 hours or as needed
Study NCT05923931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooling blanket
Description: On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
Study NCT05923931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-cooling blanket
Description: Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
Study NCT06464380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffranal
Description: HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
Study NCT06464380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HCC patients will receive Placebo in dose of once per day for six months.
Study NCT06303440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy+ Balance Training
Description: Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
Study NCT06303440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality+ Routine Physical Therapy
Description: The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
Study NCT06303440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery+ Routine Physical Therapy
Description: The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video.
Study NCT06115486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm ACSM Guidelines
Description: The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
Study NCT06115486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm 6-12-25 repetitions per set
Description: The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
Study NCT06393517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Study NCT05130814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc cream or hyaluronic acid sodium salt + metallic silver
Description: applied to prevent and/or treat the skin maceration of the surrounding area
Study NCT05130814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc cream or hyaluronic acid sodium salt + metallic silver
Description: applied to prevent and/or treat the skin maceration of the surrounding area
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: topical treatment
Description: topical treatment indicated for that stage of the lesion
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical treatment
Description: topical treatment indicated for that stage of the lesion
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bandage
Description: it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system
Study NCT05130814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bandage
Description: it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system
Study NCT06299111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9933
Description: Intravenous (IV) single dose administered
Study NCT06299111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508
Description: IV single dose administered
Study NCT06299111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV single dose administered
Study NCT06274944 — intervention group
Intervention type: DEVICE
Intervention: nasogastric tube placement pH confirmation device
Description: Each participation will get the contents tested by the novel device and the standard of care procedure.
Study NCT05789173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone and Tizanidine
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
Study NCT05789173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, Methadone and Tizanidine
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
Study NCT05395871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Message
Description: Messaging involving increased salience, increasing positive emotions and information on health consequences
Study NCT05395871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Message + Video
Description: Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
Study NCT05395871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Message
Description: Standard usual care message involving link to non-behavioural science informed video
Study NCT05675865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation procedure
Description: ablation procedure for VT using the investigational device
Study NCT04538378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
Study NCT04538378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered intravenous (IV) into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
Study NCT04538378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EKG
Description: Screening and all cycles Day 1 and Day 15 (+/- 3) days. One cycle is 28 days.
Study NCT04538378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Baseline and all cycles Day 15 (+/- 3) days. One cycle is 28 days.
Study NCT04538378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT chest, abdomen and pelvis
Description: Screening and baseline and every 8 (+/-1) weeks after start of therapy.
Study NCT04538378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI chest, abdomen and pelvis
Description: Screening and baseline and every 8 (+/-1) weeks after start of therapy.
Study NCT04793646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine syrup
Description: N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
Study NCT04793646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Placebo syrup 15 mL twice a day for 3 months
Study NCT05974579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-AP-101
Description: At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated.
Study NCT05699915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiology consultation
Description: * Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio > 15 and left atrial (LA) area > 30 cm2.
Study NCT05699915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Chest Computed Tomography (CT) without contrast
Description: Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
Study NCT05699915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-invasive endothelial function tests
Description: * FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues.
Study NCT05699915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiogram
Description: An ECG will be taken prior to each ICI cycle during the first three months of treatment.
Study NCT05699915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Extra serum sample (7.5 mL)
Description: An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
Study NCT04892173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90301900 (NBTXR3)
Description: Suspension of inert, crystalline hafnium oxide particles, designed to generate oxygen free radicals to destroy cancer cells after activation by ionizing radiation.
Study NCT04892173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Solution for infusion
Study NCT04892173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Solution for infusion
Study NCT05671718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led Treatment in Primary Care
Description: At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
Study NCT06562660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apnoeic
Description: In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
Study NCT04892173 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
Study NCT04892173 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Intensity-modulated radiation therapy (IMRT): 70 Gray in 35 fractions over a 7-week period.
Study NCT06204900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Cuff and Retractor System
Description: Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
Study NCT04655755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study NCT05717530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound site local anesthesic infiltration
Description: : at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
Study NCT05717530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plane block
Description: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
Study NCT05989022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Injection of contrast enhancing agent Gadovist for MRI investigation
Description: Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis
Study NCT05989022 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Injection of contrast enhancing agent Imeron for B-CT investigation
Description: Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
Study NCT05937308 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study NCT05211323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study NCT05211323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05211323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05211323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT05211323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV